Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Total Valuation
Lyra Therapeutics has a market cap or net worth of $7.40M. The enterprise value is ―.
Market Cap$7.40M
Enterprise Value―
Share Statistics
Lyra Therapeutics has 66,267,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,267,230
Owned by Insiders3.27%
Owned by Institutions24.14%
Financial Efficiency
Lyra Therapeutics’s return on equity (ROE) is -8.06 and return on invested capital (ROIC) is -166.52%.
Return on Equity (ROE)-8.06
Return on Assets (ROA)-1.41
Return on Invested Capital (ROIC)-166.52%
Return on Capital Employed (ROCE)-1.79
Revenue Per Employee51.13K
Profits Per Employee-3.11M
Employee Count30
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyra Therapeutics is -0.14. Lyra Therapeutics’s PEG ratio is -0.02.
PE Ratio-0.14
PS Ratio0.00
PB Ratio0.55
Price to Fair Value1.16
Price to FCF-0.14
Price to Operating Cash Flow-0.14
PEG Ratio-0.02
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 1.53M and earned -93.44M in profits. Earnings per share was -1.43.
Revenue1.53M
Gross Profit1.53M
Operating Income-96.35M
Pretax Income-93.40M
Net Income-93.44M
EBITDA-96.35M
Earnings Per Share (EPS)-1.43
Cash Flow
In the last 12 months, operating cash flow was -77.72M and capital expenditures -3.18M, giving a free cash flow of -80.90M billion.
Operating Cash Flow-77.72M
Free Cash Flow-80.90M
Free Cash Flow per Share-1.22
Dividends & Yields
Lyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change-70.27%
50-Day Moving Average0.12
200-Day Moving Average0.21
Relative Strength Index (RSI)51.47
Average Volume (3m)5.54M
Important Dates
Lyra Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Lyra Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 171.32%
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap2.56
Net Debt to EBITDA0.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyra Therapeutics has paid -39.00K in taxes.
Income Tax-39.00K
Effective Tax Rate<0.01
Enterprise Valuation
Lyra Therapeutics EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.10.
EV to Sales4.72
EV to EBITDA-0.08
EV to Free Cash Flow-0.10
EV to Operating Cash Flow-0.10
Balance Sheet
Lyra Therapeutics has $51.63M in cash and marketable securities with $35.32M in debt, giving a net cash position of -$16.30M billion.
Cash & Marketable Securities$51.63M
Total Debt$35.32M
Net Cash-$16.30M
Net Cash Per Share-$0.25
Tangible Book Value Per Share$0.18
Margins
Gross margin is -816.72%, with operating margin of -6280.83%, and net profit margin of -6090.94%.
Gross Margin-816.72%
Operating Margin-6280.83%
Pretax Margin-6088.40%
Net Profit Margin-6090.94%
EBITDA Margin-6280.83%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lyra Therapeutics is $2.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$2.00
Price Target Upside1718.18% Upside
Analyst ConsensusHold
Analyst Count3
Revenue Growth Forecast-29.46%
EPS Growth Forecast2.71%